Monogram Orthopaedics Inc... (MGRM)
| Bid | 2.48 |
| Market Cap | 95.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.33M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -5.29 |
| Forward PE | -6.65 |
| Analyst | Strong Buy |
| Ask | 2.75 |
| Volume | 31,121 |
| Avg. Volume (20D) | 656,874 |
| Open | 2.64 |
| Previous Close | 2.62 |
| Day's Range | 2.64 - 2.70 |
| 52-Week Range | 1.82 - 4.21 |
| Beta | 0.77 |
About MGRM
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for...
Analyst Forecast
According to 1 analyst ratings, the average rating for MGRM stock is "Strong Buy." The 12-month stock price forecast is $5.4, which is an increase of 100.00% from the latest price.
Stock Forecasts
1 month ago · accessnewswire.com
Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA SystemMonogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Stra...
1 month ago · seekingalpha.com
Monogram Technologies Inc. (MGRM) Q4 2024 Earnings Call TranscriptMonogram Technologies Inc. (NASDAQ:MGRM ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Larry Holub - Investor Relations Benjamin Sexson - Chief Executive Officer Noe...
1 month ago · accessnewswire.com
CORRECTION: Monogram Technologies Reports Full Year 2024 Financial ResultsThis Press Release is Acting as a Correction to the Financial Tables in the Previous Release Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Informatio...
